KeifeRx is focused on developing innovative treatment options for neurodegenerative and immune diseases, aiming to alleviate the suffering of millions affected by these conditions. The company is leveraging its extensive clinical experience to create a new generation of compounds that can effectively cross the blood-brain barrier. These compounds are designed to selectively target kinases, which play a crucial role in cellular processes, to restore autophagy—the body's way of cleaning out damaged cells—and eliminate the accumulation of toxic proteins. This approach is intended to enhance patient well-being and provide new therapeutic avenues for those suffering from debilitating diseases.

The pipeline of KeifeRx includes second-generation kinase inhibitors specifically targeting a range of neurodegenerative diseases such as Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and various forms of dementia. In addition to neurodegenerative conditions, the company is also addressing inflammatory diseases, including mast cell activated syndromes (MCAS), Lyme disease, and urticaria. By focusing on these critical areas, KeifeRx aims to deliver effective treatments that can significantly improve the quality of life for patients dealing with these challenging health issues.

United States

KeifeRx is an emerging clinical-stage biopharmaceutical company developing novel and optimized, low dose, orally delivered tyrosine kinase inhibitors (TKIs) for the treatment of multiple, high-need neurodegenerative and immune diseases.

KeifeRx

Company Details